In preclinical models, antagonizing C5aR1 with PMX53 reduces seizure severity, neuronal degeneration, and mortality, consistent with C5aR1 upregulation after status epilepticus and positioning this receptor as an anticonvulsant/anti-inflammatory target with a potentially narrower immunosuppressive footprint than proximal complement blockade. Here, C5AR1 is linked to status epilepticus.